Organogenesis Holdings Inc.
HealthcareNASDAQ:ORGO · NASDAQ Capital Market
-$0.04 today
Vol 0.76M · Avg 1.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
8.5%
avg -12.8%
ROIC
8.5%
avg -2.3%
ROA
6.2%
avg -1.8%
Analysis
ROE is currently the strongest return metric at 8.5% versus its period average of -12.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gary S. Gillheeney | President, Chief Executive Officer, Chair of the Board | $2.60M | — | 71 | $4.32M | 3.36% |
Lori H. Freedman | Chief Administrative & Legal Officer | $1.08M | — | 59 | $1.04M | 0.81% |
Brian Grow | Chief Commercial Officer | $1.05M | — | 50 | $911,123.00 | 0.71% |
Patrick Bilbo | Chief Operating Officer | $1.02M | — | 64 | $16,965.00 | 0.01% |
David C. Francisco | Chief Financial Officer | $1.00M | — | 60 | $745,561.00 | 0.58% |
Patrick McGuire | Chief Accounting Officer | — | — | 40 | $16,965.00 | 0.01% |
William R. Kolb | Secretary | — | — | — | — | — |
Robert Cavorsi | Chief Business Officer | — | — | 47 | $275,524.00 | 0.21% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$40,093.00
Sells
4
$2.62M
Net Sentiment
$2.58M
Net selling
Most Active
NUSSDORF GLENN H
4 transactions
Analysis
Insiders reported 2 buys worth $40,093.00 and 4 sells worth $2.62M over the last 12 months. That adds up to net selling of $2.58M. NUSSDORF GLENN H was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +1.2% (8yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | -1.2% (8yr)2 analysts |
Analysis
Forward estimates point to Revenue at +1.2% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
AngioDynamics, Inc.
NASDAQ:ANGO
$499.96M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
Emergent BioSolutions Inc.
NYSE:EBS
$429.28M
Monopar Therapeutics Inc.
NASDAQ:MNPR
$400.40M
SNDL Inc.
NASDAQ:SNDL
$369.44M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Who manages ORGO?
Organogenesis Holdings Inc. (ORGO) lists 8 active executives. The top listed executive is Patrick Bilbo, Chief Operating Officer.
Are ORGO insiders buying or selling?
Recent insider activity shows net selling of $21.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.